Duke University
Durham, North Carolina, United States
Dr. Chandramohan is an Associate Professor of Pathology and Neurosurgery at Duke University. Dr. Chandramohan obtained her Ph.D. in Biochemistry with a specialization in Cell and Molecular Biology at Boston University and her M.B.A. in Data Analytics from North Carolina State University. Dr. Chandramohan completed her post-doctoral training at Duke University under the mentorship of Dr. Darell Bigner, where she developed the dual specific immunotoxin (IT), D2C7-IT, targeting the wild-type epidermal growth factor receptor (EGFRwt) and its mutant EGFR variant III (EGFRvIII), the two common oncogenes of the most malignant brain tumor, glioblastoma (GBM). D2C7-IT monotherapy (NCT02303678), D2C7-IT+Atezolizumab (NCT04160494), and D2C7-IT+2141-V11 (αCD40) (NCT04547777 and NCT05734560) combination therapies are currently in Phase I clinical trials in patients with GBM. Her current research includes identifying novel strategies to activate the tumor immune microenvironment to enhance the efficacy of D2C7-IT and investigating tumor and immune-related biomarkers to predict the clinical outcome of D2C7-IT and D2C7-IT based combination therapies in patients with GBM. In addition to developing targeted therapies and associated biomarkers, Dr. Chandramohan’s research also focuses on conducting phenotypic and genotypic characterization of tumor and immune cells at the single-cell level in brain tumors by applying multi-omics technology.
